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To determine the safety and efficacy of synchronized coronary 
venous retroperfusion during brief periods of ischemia, 30 pa-
tients undergoing angioplasty of the left anterior descending 
coronary artery were studied. Each patient underwent a mini-
mum of two angioplasty balloon inflations. Alternate dilations 
were supported with retroperfusionj the unsupported inflations 
served as the control inflations. Synchronized retroperfusion was 
performed by pumping autologous femoral artery blood by means 
of an electrocardiogram-triggered retroperfusion pump into the 
great cardiac vein through a triple lumen 8.5F balloon-tipped 
retroperfusion catheter inserted percutaneously from the right 
internal jugular vein. Clinical symptoms, hemodynamics and 
two-dimensional echocardiographic wall motion abnormalities 
were analyzed. 
Retroperfusion was associated with a lower angina severity 
score (0.8 ± 1 vs. 1.2 ± 1) and delay in onset of angina (53 ± 31 
vs.37 ± 14 Sj P < 0.05) compared with the control inflations. The 
magnitude of ST segment change was 0.11 ± 0.14 mV with 
retroperfusion and 0.16 ± 0.17 mV without treatment (p < 0.05). 
The severity of left ventricular wall motion abnormality was also 
Percutaneous transluminal coronary angioplasty is an effec-
tive treatment for coronary artery stenosis, but results in 
transient interruption of regional blood supply, which can 
cause myocardial ischemia with consequent hemodynamic, 
electrophysiologic, metabolic and functional derangements 
(1-3). These ischemic changes are of particular concern in 
patients with a large area of jeopardized myocardium or 
significant preexisting left ventricular dysfunction. Further-
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significantly (p < 0.01) reduced with retroperfusion compared 
with control (0.7 ± 1.4 [hypokinesia] vs. -0.3 ± 1.6 [dyskinesia]). 
There were no significant changes in hemodynamics, except in 
mean coronary venous pressure, which increased from 8 ± 
3 mm Hg at baseline to 13 ± 6 mm Hg with retroperfusion. Four 
patients required prolonged retroperfusion for treatment of an-
gioplasty-induced complications. The mean retroperfusion dura-
tion in these patients was 4 ± 2 h (range 2 to 7). In the three 
patients who underwent emergency bypass surgery, the coronary 
sinus was directly visualized during surgery and found to be 
without significant injury. 
There were no major complications. Minor adverse effects 
were transient atrial fibrillation (n = 2), jugular venous catheter 
insertion site hematomas (n = 4) and atrial wall staining (n = 1), 
all of which subsided spontaneously. Thus, retroperfusion signif-
icantly reduced and delayed the onset of coronary angioplasty-
induced myocardial ischemia and provided effective supportive 
therapy for failed and complicated angioplasty. 
(J Am Coli CardioI1991;18:271-82) 
more, acute closure of the dilated coronary artery occurs in 
approximately 5% of all angioplasty procedures (4). This 
complication is usually managed by coronary bypass surgery 
but may sustain a mortality rate as high as 7% (5,6). 
Among techniques employed in an attempt to mitigate 
these ischemic derangements are the administration of phar-
macologic agents and infusion of oxygenated fluorocarbon 
solutions or arterial blood through the angioplasty catheter 
(7-11). These techniques allow extension ofthe angioplasty 
balloon inflation time, but have certain limitations. The 
requirement of some of the latter techniques for a larger 
catheter system limits their ability to cross a severely 
stenotic lesion or pass distally within a tortuous vessel. 
Perfusion may also be ineffective when there are additional 
sequential stenoses or when the perfusion catheter obstructs 
a significant side branch. Percutaneous femorofemoral car-
diopulmonary bypass, hemopump left ventricular assist and 
intraaortic balloon pumping devices may provide systemic 
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circulatory support and reduce myocardial oxygen demand; 
however, blood supply to the jeopardized myocardium is not 
enhanced by these techniques and therefore myocardial 
ischemia may persist (12-14). 
Synchronized coronary venous retroperfusion is a tech-
nique that provides perfusion of the patient's arterial blood 
to the jeopardized myocardium retrogradely through the 
coronary veins. Because perfusion is retrograde rather than 
anterograde, its efficacy is not influenced by the number, 
location or degree of stenoses, tortuosity or branching of the 
coronary artery. This method has been extensively investi-
gated in animals (15-22) and has been shown to provide 
significant myocardial support in preliminary clinical studies 
(23-30). 
Coronary angioplasty offers a unique opportunity to 
examine the physiologic response to recurrent transient 
ischemic episodes (3). Therefore, using angioplasty as a 
short and reproducible ischemic model, the efficacy of 
various support systems has been studied (7-13). The pur-
pose of the present study was to determine the safety and 
efficacy of a new synchronized coronary venous retroperfu-
sion system (Retroperfusion Systems, Inc.) in this ischemic 
model. 
Methods 
Study design. The study included 43 patients with ~70% 
stenosis of the left anterior descending artery scheduled for 
angioplasty of the artery at Cedars-Sinai Medical Center. 
The patients were selected if the investigator believed that 
balloon inflation would result in significant ischemia by 
obstruction of blood flow to the first septal perforator or a 
large first diagonal branch of the left anterior descending 
coronary artery. Informed consent was obtained from all 
patients with use of an institutional and Food and Drug 
Administration-approved human investigation form. In all 
patients, a 9F sheath was introduced percutaneously into the 
right internal jugular vein for insertion of the retroperfusion 
catheter, followed by placement of 8F arterial sheaths in 
both femoral arteries. 
Coronary angioplasty. Coronary angioplasty was per-
formed in the standard manner. The effects of a minimum of 
two angioplasty balloon inflations were studied in each 
patient. Retroperfusion was applied during alternate balloon 
inflations, the order of which was randomized. In some 
patients, the first angioplasty balloon inflation was of brief 
duration (30 s) and performed to ensure proper positioning of 
the balloon within the stenosed segment of the coronary 
artery. This inflation was not included in the analysis. 
All patients received heparin to maintain the activated 
clotting time between 360 and 480 s. Hemodynamic variables 
(heart rate, aortic blood pressure and coronary venous 
pressure) and a single precordial electrocardiographic (ECG) 
lead (V 3 to V J was monitored and continuously recorded at 
25 mmls on an Electronics for Medicine VR-12 physiologic 
recorder. 
Figure 1. Triple lumen 8.5F balloon-tipped gas inflatable retroper-
fusion catheter. (Reproduced with permission from Retroperfusion 
Systems, Inc., Costa Mesa, California.) 
The time to onset of angina was determined during all 
unsupported and retroperfusion-supported-balloon infla-
tions. The severity of the pain was assessed on a semiquan-
titative scale of 0 to 4 (0 = no pain, 1 = mild, 2 = moderate, 
3 = severe, 4 = intolerable). ST segment change was 
measured 0.06 s after the J point and expressed as absolute 
change from the baseline measurement. 
Quantitative two-dimensional echocardiography. Two-
dimensional echocardiograms were recorded before and 
during each balloon inflation in apical two- or four-chamber 
views using an Advanced Technology Laboratories Ultra 
Mark VIII echocardiograph. The echocardiographic win-
dow, contrast settings and depth were optimized during 
baseline imaging and then kept constant throughout the 
study. The images were digitized from videotape into a cine 
loop format using a commercial computerized analysis sys-
tem (Microsonics, Inc.). Because the duration ofthe treated 
and control balloon inflations was not identical, the un-
treated being of shorter duration, echocardiographic images 
during treated inflations were analyzed at similar durations 
as the matched untreated inflations. A modified centerline 
analysis method as described by Jaffe et al. (9) was used to 
quantify extent and severity of regional left ventricular wall 
motion abnormality. Extent was expressed as the total 
number of chords of the entire left ventricular perimeter that 
were affected. Severity was the degree of percent chordal 
shortening in the 10 most affected contiguous chords. Global 
left ventricular ejection fraction was calculated with the 
modified Simpson's rule. 
The retroperfusion system. The retroperfusion device 
consists of an electronic pumping console, a specially de-
signed retroperfusion catheter (Fig. 1) and an arterial cath-
eter. Arterial blood is withdrawn from the femoral artery 
through a 25 cm long 8F catheter, featuring end and mUltiple 
side holes. This catheter is introduced through a sheath 
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Figure 2. Schematic representation of the method by which syn-
chronized coronary venous retroperfusion is accomplished. Arterial 
blood is obtained from the femoral artery and shunted through the 
pump console into the great cardiac vein by means of the retroper-
fusion catheter. AI = anterior interventricular; EM = electromag-
netic; LAD = left anterior descending coronary artery; PICA = 
percutaneous transluminal coronary angioplasty; SRP = synchro-
nized retroperfusion. 
placed in the femoral artery not used for angioplasty. The 
arterial catheter is connected to the inlet of the disposable 
retroperfusion pump cassette, which is housed within the 
system console. Arterial blood is pumped during diastole by 
means of a piston whose motion is triggered by the R wave 
of the monitored ECG. The outlet of the pumping cassette is 
connected to the infusion lumen of the coronary sinus 
catheter (Fig. 2), which is a radiopaque 8.5F triple lumen 
catheter, featuring an inflatable balloon located 1 cm from 
the distal end of the catheter. Carbon dioxide gas is delivered 
through the catheter's second lumen to inflate the balloon 
during diastole (maximal diameter lO mm at full inflation). 
The third retroperfusion catheter lumen is used to monitor 
coronary venous pressure. During systole, the retroperfu-
sion flow is interrupted and the balloon deflated to facilitate 
coronary venous drainage. 
Coronary sinus catheterization. An attempt was made in 
each case to place the catheter deep into the coronary sinus, 
preferably into the great cardiac vein with the tip of the 
catheter distal to the posterior vein of the left ventricle. 
Contrast material was hand-injected through the infusion 
lumen of the catheter into the coronary veins with the 
catheter balloon inflated to confirm both adequate catheter 
positioning and proper occlusion of the coronary vein by the 
balloon (Fig. 3). In three patients, a guide wire was used to 
facilitate catheter placement. 
Modifications of the retroperfusion system. Changes were 
made in the catheter configuration and pump system during 
the course of the study. The objective was to optimize the 
retroperfusion system to permit use of larger diameter bal-
loons on the retroperfusion catheter and obtain higher flow 
levels, and consequently higher coronary venous pressures, 
and thus be able to perform retroperfusion from proximal 
positions in the coronary sinus when distal catheter place-
ment was not possible. The first eight patients were studied 
with use of an autoinflatable balloon retroperfusion catheter 
with two lumens and a maximal flow rate of 96 mllmin. The 
next eight were studied with use of a triple lumen gas-
activated balloon catheter with dual-valve pumping cas-
settes, providing maximal flow rates of 124 mllmin. The last 
14 patients were studied with use of the same triple lumen 
gas-activated retroperfusion catheter, but with a bladder 
pump cassette delivering maximal flow rates of 250 mllmin. 
Statistics. All data are presented as mean values ± 1 SD. 
The change from preangioplasty balloon inflation to peak 
angioplasty balloon inflation in hemodynamic variables, 
magnitude of ST segment change and echocardiographic 
data was analyzed by the two-tail paired t test. Comparisons 
between the untreated and retroperfusion balloon inflation 
groups were made by the unpaired t test with these excep-
tions: the time of onset of chest pain and severity score of 
angina were analyzed by the Mann-Whitney rank-sum test 
and the incidence of ST segment change and angina was 
compared with chi-square analysis. 
Results 
Feasibility. Catheterization of the coronary sinus was 
successful in 36 (84%) of 43 patients, with a mean insertion 
time of2.6 min (range 0.5 to 10) after the catheter was placed 
in the right atrium. Of the seven unsuccessful cases, the 
jugular vein could not be catheterized in three, the catheter 
could not be placed in the coronary sinus in three and 
fluoroscopy demonstrated staining of the right atrial wall 
after contrast injection through the catheter in one case. In 
this patient no further attempts at coronary sinus catheter-
ization were made, the staining disappeared after 10 min and 
the patient's echocardiogram was normal. Six of the 36 
patients undergoing catheterization did not complete the 
study. In three of the six, coronary angioplasty could not be 
performed for technical reasons; in one patient, ventricular 
fibrillation developed during the first control angioplasty 
balloon inflation and the patient was sent directly for coro-
nary bypass surgery and in two patients, a stable coronary 
venous catheter position could not be maintained with 
pumping. 
The retroperfusion technique was thus feasible in 34 
(79%) of 43 patients, but because of the reasons just enu-
merated, only 30 patients completed the protocol. These 
patients underwent 128 angioplasty balloon inflations: 61 
inflations were treated with synchronized retroperfusion and 
67 were untreated. The mean duration of the retroperfused 
and untreated inflations was 81 ± 21 and 73 ± 18 s, 
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respectively (p < 0.01). The clinical characteristics of the 30 
patients are listed in Table 1. 
Hemodynamics. Heart rate and diastolic blood pressure 
did not change significantly during retroperfusion, but sys-
tolic pressure decreased significantly during untreated balloon 
inflations (from 125 ± 22 to 108 ± 24 mm Hg) and during 
retroperfusion (from 120 ± 22 to 111 ± 21 mm Hg). The mean 
coronary venous pressure was 13 ± 6 mm Hg (range 4 to 26) 
with retroperfusion compared with 8 ± 3 mm Hg (range 1 to 14) 
without retroperfusion (p < 0.01). The peak coronary venous 
pressure was 29 ± 12 mm Hg (range 6 to 59) with retroperfu-
sion and 12 ± 5 mm Hg (range 4 to 26) without retroperfusion 
(p < 0.01) (Fig. 4), Coronary venous pressure did not change 
during angioplasty balloon inflations. 
Angina. Angina occurred in 40% of the angioplasty bal-
loon inflations supported by retroperfusion and in 53% of the 
unsupported inflations. The time to onset of angina was 53 ± 
Figure 3. Coronary venograms of two patients 
during left anterior descending artery angio-
plasty, showing proximal filling of all the tribu-
taries of the coronary veins and regurgitation 
past the nonocclusive synchronized retroperfu-
sion catheter balloon (A) and distal penetration 
of the retroperfusate as a result of adequate 
retroperfusion balloon catheter position (B). 
The venograms were obtained by injecting con-
trast material into the retroperfusion pump sys-
tem (right anterior oblique view). AIV = ante-
rior interventricular vein; B = retroperfusion 
catheter balloon; GCV = great cardiac vein; 
MCV = middle cardiac vein; PICA = angio-
plasty balloon; PV = posterior vein of the left 
ventricle; SRP Cath = coronary sinus retroper-
fusion catheter; W = angioplasty guide wire. 
31 s in the retroperfusion-supported inflations compared 
with 37 ± 14 s without retroperfusion (p < 0.05). The angina 
severity score was 0.8 ± 1 with retroperfusion compared 
with 1.2 ± 1 without retroperfusion (p < 0.05). 
ST segment changes. ST segment change (;:::0.1 mY) 
occurred in 46% of the balloon inflations with retroperfusion 
compared with 52% of the control inflations. The magnitude 
of the ST segment change was 0.11 ± 0.14 mY with 
retroperfusion and 0.16 ± 0.17 mY without retroperfusion 
(p < 0.05), despite longer duration of the inflations supported 
with retroperfusion. 
Two-dimensional echocardiography (Table 2). Echocar-
diograms were recorded in 23 of the 30 patients. Quantitation 
of the echocardiograms was not possible in eight patients 
because of poor image quality. Moreover, two patients did 
not develop any ischemia during the angioplasty balloon 
inflations performed without retroperfusion and were not 
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Table 1. Demographics of the 30 Patients Who Completed the Study Protocol 
Age 
Pt (yr)1 
Past History Symptoms Medication 
Assoc 
Diseases 
Cardiac 
Catheterization Data 
No.ofPTCA 
Inflations 
No. Gender 
Weight 
(kg) MI PTCA CABG CCS NTG CB BB ASA DM HTN RCA LCx LAD LMCA 
SRP-
EF(%) Untreated Supp 
2 
54/M 
841M 
67/M 
4* 64/M 
5 52/F 
6 601M 
7 53/M 
8 53/M 
9' 731M 
10 50/F 
11 
12 
13 
14 
15 
46/M 
49/M 
501M 
48/M 
62/M 
16 561M 
17 63/M 
18 391M 
19 69/M 
20 49/M 
21 47/M 
77 
80 Ant 
82 
91 
36 
85 Ant 
85 Inf 
75 
67 
86 
91 
77 
82 
78 
Ant 
80 Ant, inf 
73 
64 
59 
84 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
4 
4 
4 
4 
4 
4 
+ 
+ + 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + + 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ Ocd 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
>55 
>55 
>55 
>55 
>55 
35-55 
35-55 
>55 
>55 
>55 
>55 
35-55 
>55 
>55 
>55 
>55 
<35 
<35 
+ >55 
+ >55 
+ <55 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
1 
2 
2 
2 
2 
2 
4 
2 
2 
22 711F 70 + 
+ 
4 
2 
4 
4 
4 
4 
4 
4 
2 
4 
+ + + + + Narrowing <35 
2 
2 
3 
4 
5 
23 73/F 66 Inf + + + + + 
+ 
+ 
+ 
+ 
+ Narrowing <35 
24 62/M 
25 68/M 
26 40/F 
27* 72/F 
28 
29 
30 
421M 
56/M 
751F 
73 
75 Ant 
89 
66 Ant 
89 
91 
63 + + 
4 
2 
4 
4 
+ 
+ + + 
+ + 
+ 
+ + 
+ + 
+ + 
+ 
+ 
+ 
+ 
+ + 
+ 
+ + 
+ 35-55 
+ 
+ 
35-55 
35-55 
+ Stenosis, 35-55 
+ 
+ 
thrombus 
+ Narrowing 
35-55 
35-55 
<35 
2 
4 
2 
2 
2 
2 
2 
4 
2 
2 
'Prolonged retroperfusion; Ant = anterior; ASA = aspirin; Assoc = associated; BB = beta-blocker; CABG = coronary artery bypass grafting; CB = calcium 
channel blocker; CCS = Canadian Cardiovascular Society class; DM = diabetes mellitus; EF = left ventricular ejection fraction; F = female; HTN = 
hypertension; Inf = inferior; LAD = left anterior descending coronary artery; LCx = left circumflex coronary artery; LMCA = left main coronary artery; M = 
male; MI = myocardial infarction; NTG = nitroglycerin; Occl = total occlusion; PTCA = coronary angioplasty; RCA = right coronary artery; SRP-Supp = 
retroperfusion-supported; patient numbers in italics indicate patients with analyzable echocardiograms; - = missing data. Note: All coronary artery stenoses are 
marked positive only if >70% narrowing except of the left main lesion. 
included in the analysis. Therefore, echocardiograms were 
analyzed in 13 patients. 
Global function (Table 2). Left ventricular ejection frac-
tion decreased from 51 ± 13% to 43 ± 8% (p < 0.05) with 
angioplasty balloon inflations supported by retroperfusion 
compared with 52 ± 9% to 32 ± 10% (p < 0.01) in the 
untreated inflations. The difference in ejection fraction 
change was statistically significant (p < 0.01) between 
groups (Fig. 5A). 
Regional function (Table 2). The ischemic zone percent 
chordal shortening decreased from 1.5 ± 1.7% at baseline to 
0.7 ± 1.4% (mild hypokinesia) during the balloon inflations 
with retroperfusion, whereas in the control inflations, the 
ischemic zone percent chordal shortening decreased from 
1.6 ± 1.6% to -OJ ± 1.6% (p < 0.01), the negative value 
indicating dyskinesia of the regional wall (Fig. 5B). The 
difference in percent chordal shortening during angioplasty 
without and with retroperfusion reached statistical signifi-
cance (p < 0.01). The extent of left ventricular wall motion 
abnormality during the angioplasty balloon inflation was 
significantly less with retroperfusion (21 ± 9%) compared 
with that during inflation without retroperfusion (36 ± 12%) 
(p < 0.01) (Fig. 5C). 
Hematology. The mean red blood cell counts, hemato-
crit, hemoglobin and platelet counts were 4.5 million/mm3, 
40.4%, 13.7 g/dl and 212,OOO/mm3, respectively, before ret-
roperfusion and 4.4 million/mm3, 39.8%, 13.3 g/dl and 
205,OOO/mm3 after completion of the protocol. The plasma-
free hemoglobin increased from 5.6 mg/dl before retroperfu-
sion to 21.7 mg/dl after retroperfusion (p = 0.25). These 
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Figure 4. Mean and maximal coronary venous pressure with and 
without synchronized retroperfusion (SRP) at three different flow 
rates in all the patients. Triangles = retroperfusion flow rate of 83 ± 
12 mVmin; closed circles = flow rate of 115 ± 10 mVmin; open circles 
= retroperfusion flow rate of 203 ± 44 mVmin. 
values include the four patients who underwent prolonged 
retroperfusion pumping. 
Complications. There were no major complications due 
to retroperfusion. Minor adverse effects included transient 
atrial fibrillation (n = 2), hematoma at the internal jugular 
vein insertion site (n = 4) and atrial wall contrast agent 
staining (n = O. All these complications resolved completely 
without specific therapy. 
RetroperJusion During Complicated/Failed 
Angioplasty,' Case Reports 
Four patients required longer periods of synchronized 
retroperfusion because of postangioplasty abrupt occlusion 
in three patients and intolerable angina during the untreated 
angioplasty balloon inflations in the fourth patient. 
Table 2. Echocardiographic Results in 13 Patients 
Baseline 
Regional function 
Untreated 
Balloon Inflations 
Case 1 (Fig. 6). A 64 year old man presented with 
progressive exertional angina due to a 95% proximal left 
anterior descending coronary artery stenosis involving the 
first septal perforator (Fig. 6A). Five minutes after comple-
tion of the angioplasty-retroperfusion protocol, he suddenly 
developed severe chest pain, hypotension (blood pressure 
<60 mm Hg) and complete heart block; global hypokinesia 
was seen on the echocardiogram (Fig. 6C). Intracoronary 
nitroglycerin, right ventricular pacing and dopamine infusion 
did not reverse the cardiogenic shock, which was deter-
mined by angiography to be due to postangioplasty total 
occlusion of the proximal left anterior descending coronary 
artery (Fig. 6B). The retroperfusion catheter was reposi-
tioned and retrograde pumping begun in the hope of main-
taining viability of the jeopardized myocardium. Within 
minutes the chest pain abated, blood pressure stabilized at 
90 to 100 mm Hg and echocardiography showed marked 
improvement in global wall motion of the left ventricle (Fig. 
6C). The patient was supported by retroperfusion for 2.5 h 
while several angioplasty balloon dilations were attempted 
but failed and the patient was sent for emergency coronary 
bypass surgery. The patient underwent successful double-
vessel bypass grafting. The coronary sinus appeared normal 
on direct visualization during surgery. The patient had an 
uneventful hospital course and left the hospital with a left 
ventricular ejection fraction of 61% on radionuclide scans. 
Case 2. A 73 year old man with diabetes, hypertension 
and a past history of myocardial infarction presented with 
severe chest pain. The ECG revealed complete right bundle 
branch block and the coronary angiogram showed 30% 
stenosis of the left main coronary artery, two severe serial 
stenoses in both the mid left anterior descending and prox-
imalleft circumflex coronary arteries and a severe proximal 
stenosis in the right coronary artery. During the angioplasty 
procedure for the left coronary arteries, both vessels kept 
intermittently occluding with development of significant 
ischemia as evidenced by severe angina. Echocardiograms 
were not recorded in this patient. Retroperfusion was per-
formed throughout the 2 h angioplasty procedure with relief 
of the angina. Eventually both vessels were dilated with 
residual stenoses of 40%, but the patient died 7 days later. 
Balloon 
Inflation Baseline 
Retroperfusion 
During Inflations 
Balloon 
Inflation 
Severity WMA (%CS) 1.6 ± 1.6 -0.3 ± 1.6' 1.5±1.7 0.7 ± l.4t 
Extent WMA (%L V) 36 ± 12 21 ± 9t 
Global function 
Ejection fraction (%) 52 ± 9 32 ± 10' 51 ± 13 43 ± 8H 
*p < 0.01 versus baseline, tp < 0.01 versus untreated; tp < 0.05. %CS == percent chordal shortening; %LV == 
percent of the left ventricle; WMA == wall motion abnormality. 
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Figure 5. Echocardiographic findings in 13 patients. A, Ejection 
fraction by the centerline method. The individual and mean ejection 
fractions obtained by quantitation of the two-dimensional echocar-
diogram in both the retroperfusion-supported and unsupported 
(untreated) inflations before (PRE INF.) and during (PICA INF.) 
angioplasty balloon inflation. B, Severity of wall motion abnormality 
(expressed as percent chordal shortening) obtained by quantitation 
of the apical four chamber echocardiogram by the centerline 
method, showing individual and mean values for the groups with and 
without retroperfusion support before (PRE INF.) and during 
(PICA INF.) angioplasty balloon inflation. C, Individual and mean 
values for the extent of the left ventricle (LV) with severe wall 
motion abnormality during angioplasty balloon inflation (expressed 
as a change from the baseline) in the inflations with and without 
retroperfusion support. See text for p values. 
At postmortem examination, the cause of death was found to 
be a fresh infarction in the left circumflex coronary artery 
territory. The coronary sinus and veins were normal. 
Case 3 (Fig. 7). A 72 year old woman with diabetes, 
hypertension and congestive heart failure presented with 
unstable angina and anterolateral ischemic ECG changes. 
She had 90% complex stenoses of both the proximal left 
anterior descending (Fig. 7 A) and left circumflex coronary 
arteries and severe sequential stenoses of the right coronary 
artery. The angioplasty procedure of the proximal left ante-
rior descending coronary artery was complicated by rupture 
of the angioplasty balloon two times, followed by dissection 
of the left main coronary artery (Fig. 7B). The angioplasty 
procedure was therefore abandoned. The patient underwent 
prophylactic retroperfusion during the angioplasty proce-
dure and while awaiting coronary bypass surgery; retroper-
fusion continued for a total of 7 h from the start of angio-
plasty to the institution of cardiopulmonary bypass in the 
operating room, during which time she was clinically stable. 
At operation, the coronary sinus was found to be normal and 
there was no evidence of acute myocardial infarction. At 1 
year, the patient is asymptomatic and the ECG shows only a 
loss of the R wave in lead VI along with the preexisting 
anterolateral ischemic changes. 
Case 4. A 62 year old man was admitted to the hospital 
with unstable angina. Angiography revealed two discrete 
95% proximal stenoses of the left anterior descending coro-
nary artery. During angioplasty, he began complaining of 
severe angina when the guidewire was inserted across the 
lesion even before the angioplasty balloon catheter was 
inserted. Synchronized retroperfusion was started and alle-
viated the angina. Echocardiograms were not recorded in 
this patient. Retroperfusion was continued during 13 succes-
sive angioplasty balloon inflations and thus the patient had to 
be excluded from the protocol because control inflations 
were not possible. Because angioplasty was not successful, 
the patient underwent coronary bypass surgery with saphe-
nous vein grafts to the diagonal, circumflex and posterior 
descending arteries and an internal mammary graft to the left 
anterior descending coronary artery. The coronary sinus and 
veins were normal. The patient is asymptomatic at 2 years. 
Discussion 
In this study in 36 patients coronary sinus retroperfusion 
during balloon angioplasty was safe, feasible and effective in 
ameliorating and delaying the onset of ischemia. Further-
more, retroperfusion provided myocardial support during 
complicated and failed angioplasty and reversed cardiogenic 
shock in one patient. 
Safety of the retroperfusion technique. There are three 
safety issues: 1) safety of coronary sinus catheterization 
through the jugular vein; 2) the effects of retroperfusion on 
the coronary venous system; and 3) the effects of retroper-
fusion on the formed blood elements. Coronary sinus cath-
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eterization is a safe technique for measuring coronary blood 
flow (31-33). In our study, the small hematomas at the 
jugular venous insertion site could probably have been 
avoided by a left brachial artery approach. Nevertheless, the 
hematomas resolved without specific treatment and no pa-
tient required blood transfusion. Atrial fibrillation occurred 
probably secondary to irritation of the atrial wall. It resolved 
spontaneously and was not associated with any chest pain or 
hemodynamic effects. In one patient, there was evidence of 
injury to the atrial wall as demonstrated by staining after 
contrast injection through the retroperfusion catheter. How-
ever, because of the injury , retroperfusion was not employed 
to avoid the potential for extensive damage. 
The effects of synchronized retroperfusion on the coro-
nary sinus and coronary veins have been studied extensively 
in the experimental model (15-22) and humans (23-30). On 
direct visualization of the coronary sinus in three patients 
undergoing coronary bypass surgery and in one patient at 
postmortem examination, Gore et al. (28) noted minor bruis-
Figure 6. Case I . Left coronary artery angiogram 
taken before angioplasty, showing tight proximal 
stenosis in the left anterior descending coronary 
artery (arrow) but with some distal filling (A) and 
after angioplasty when the patient was in cardio-
genic shock, showing total occlusion of the artery 
(arrow) and very poor distal filling (B) . C, End-
systolic two-dimensional echocardiographic im-
ages recorded during abrupt occlusion of the left 
anterior descending coronary artery as a result of 
dissection (left) and after 150 min of retroperfusion 
(right) . Note the severe global hypokinesia of the 
left ventricle during shock, which was reversed to 
normal contraction after retroperfusion as repre-
sented by the significantly reduced end-systolic 
cavity. 
ing of the coronary sinus and one instance of a microscopic 
nonocclusive thrombus. These findings were corroborated in 
our study, in which the coronary sinus was visualized in the 
three patients who were sent for coronary bypass surgery 
and one in whom a postmortem study was performed. The 
coronary sinus was normal in three and only superficially 
bruised in one. 
Previous studies (16,17) indicate that severe damage to 
venules occurred when coronary venous pressures exceed 
60 mm Hg peak or 40 mm Hg mean pressure. In our study, 
the average mean and peak coronary venous pressures were 
kept well below those levels at 13 ± 6 and 29 ± 12 mm Hg, 
respectively. The pump is equipped with a safety mechanism 
that terminates retroperfusion when coronary venous pres-
sures exceed prescribed limits. 
We also confirmed prior studies (16,28) that showed no 
significant changes in red cell, white cell and platelet counts 
or plasma-free hemoglobin levels. Thus, the safety of the 
retroperfusion technique was confirmed in the current study 
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Figure 7. Case 3. Left coronary angiogram 
taken before angioplasty, showing tight proxi-
mal stenosis in the left anterior descending A 
coronary artery (arrow) (A) and after angio-
plasty, showing left main coronary artery dis-
section (arrow) (B). This patient underwent 
retroperfusion for 7 h and was clinically stable 
until she underwent cardiopulmonary bypass in 
the operating room. 
by the absence of any hemodynamic, hematologic, morpho-
logic or clinically evident adverse effects. 
Optimization of the retroperfusion technique. It has been 
suggested by previous studies (20,27,34) that high flows and 
increased coronary venous pressures are required to over-
come the rich alternating drainage that may shunt the 
retroperfusate away from the ischemic bed. Therefore, the 
system was modified to increase the maximal flow rate from 
100 to 250 mllmin. An attempt was made to correlate flow 
rate, coronary venous pressure, catheter position and effi-
cacy. There was significant correlation (p < 0.01) between 
retroperfusion flow rate and coronary venous pressure; 
however, differences in echocardiographic wall motion 
could not be appreciated because of the small number of 
patients (n = 4) in the groups with different flow rates. In the 
three patients in whom there was no efficacy, the catheter tip 
was very proximal in the coronary sinus and venography 
showed inadequate retrograde penetration of the contrast 
material. Thus, efficacy is related to multiple factors, in-
cluding flow rate, coronary venous anatomy, catheter posi-
tion relative to the site of coronary artery obstruction and 
pressure gradient between the coronary venous and distal 
arterial beds, as shown by Meesman et al. (35) in a canine 
model. 
Feasibility of the technique. Feasibility of retroperfusion 
involves three issues: ease and rapidity of apphcatlon, 
special training requirements and patient applicability. The 
retroperfusion catheter was successfully positioned in 84% 
of patients and the technique was feasible in 79%. Catheter 
placement took 2.5 min (range 0.5 to 10) after placement of 
the catheter in the right atrium; this timing included the time 
taken by both experienced and inexperienced physicians 
who attempted the technique. An additional 20 min was 
required to prime the pump and start synchronized retro-
perfusion. Neither a perfusionist nor a surgical team was 
required. Moreover, retroperfusion has been used success-
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fully in hospitals lacking a catheterization laboratory, in-
traaortic balloon pump or cardiac surgery facilities (29,30). 
In this study, patients between 18 and 85 years of age 
were included; therefore, patient age was not a contraindi-
cation to retroperfusion. We limited the use of retroperfu-
sion to left anterior descending coronary artery support. The 
efficacy of retroperfusion in the reduction of left circumflex 
coronary artery ischemia in evolving myocardial infarction 
was reported by Barnett and Touchon (29). 
Efficacy of retroperfusion. Experimental studies (15-22) 
of retroperfusion during acute ischemia have demonstrated a 
significant reduction in infarct size, enhanced myocardial 
perfusion, restoration of glucose metabolism and significant 
improvement in left ventricular function. Clinical studies 
(23-29) have suggested efficacy in the treatment of unstable 
angina, acute myocardial ischemia and as an adjunct during 
balloon angioplasty in the left anterior descending coronary 
artery distribution. 
In this study the effects of retroperfusion on brief left 
anterior descending coronary artery occlusion during angio-
plasty were studied in patients who were predicted to 
develop severe ischemia. Moreover, in this study design, 
each patient was his or her own control. No patient had left 
bundle branch block or QS patterns on the ECG in the region 
of interest, which could also affect the results. The efficacy 
of retroperfusion was demonstrated by significant diminu-
tion and delay in the onset of ischemia, as evidenced by left 
ventricular wall motion, angina and ST segment change. 
This efficacy suggests that retroperfusion may be used 
prophylactically as a device for "supported angioplasty" in 
high risk patients, as described by Vogel et al. (14) when 
defining the role of cardiopulmonary bypass in high risk 
angioplasty. Also, in cases where prolonged angioplasty 
balloon inflation times are required, the support of retroper-
fusion may be beneficial. Retroperfusion was not effective in 
all patients, but in the majority of patients the ischemic 
response was delayed or decreased although not totally 
abolished. The role of this technique, therefore, is as a 
prophylactic support technique during high risk and complex 
angioplasty rather than for routine angioplasty. 
Prolonged retroperfusion for complicated angioplasty. 
The complication rate of coronary angioplasty in this study 
was 13%. This high rate may be attributed to the fact that 
patients predicted to develop significant ischemic events 
were selected. Abrupt occlusion occurred in two patients 
(Cases 1 and 2), reSUlting in cardiogenic shock and severe 
angina, respectively. In both patients conventional therapy 
was unsuccessful, but retroperfusion promptly reversed the 
ischemia. Thus, retroperfusion can reverse cardiogenic 
shock due to abrupt coronary occlusion during angioplasty 
and is helpful in difficult and prolonged multivessel angio-
plasty complicated by symptomatic vessel closure. 
Left main coronary artery dissection developed during 
angioplasty of the left anterior descending coronary artery in 
another patient (Case 3). This is a rare complication that has 
been reported by Lotan et al. (36). This patient also had a 
thrombus in the left anterior descending coronary artery and 
was thus at greater risk for abrupt occlusion (27). Even 
though she was asymptomatic and hemodynamically stable, 
retroperfusion was performed prophylactically because of 
her high risk for a sudden severe ischemic event. This case 
suggests that synchronized retroperfusion may be helpful if 
kept as standby during high risk angioplasty. 
Case 4 illustrates the development of severe ischemia due 
to occlusion by a guide wire of a coronary artery supplying 
a large portion of viable myocardium. The patient's severe 
chest pain was refractory to intracoronary nitroglycerin. 
Retroperfusion decreased the chest pain and allowed the 
patient to undergo angioplasty, although the latter was 
unsuccessful and emergency coronary bypass surgery was 
required. This case suggests the efficacy of retroperfusion in 
difficult angioplasty, where the ischemia is so significant that 
occasionally the procedure has to be abandoned. 
It has been reported (37,38) that the incidence of Q wave 
infarction is 55% to 77% and the mortality rate 5% to 12% in 
patients requiring emergency coronary bypass surgery after 
failed angioplasty. The risk is greater when the failed angio-
plasty is complicated by hemodynamic instability or the 
presence of ischemic symptoms (39). All three patients in 
our study who required emergency bypass surgery were in 
the greater risk group and yet did not develop Q waves or die 
after surgery. 
These cases suggest that retroperfusion is an effective 
support system in the event of angioplasty-induced compli-
cations. However, immediate permanent revascularization 
should always be the goal of therapy, retroperfusion provid-
ing a bridge until reperfusion is established. 
Retroperfusion and other myocardial support techniques. 
Systemic support systems (namely, the intraaortic balloon 
pump, percutaneous cardiopulmonary bypass and hemo-
pump left ventricular assist devices) maintain peripheral 
perfusion and systemic hemodynamics but have no direct 
myocardial protective effects. In contrast, retroperfusion 
provides nutrient blood flow to the myocardium and en-
hances washout of toxic metabolites from underperfused 
areas but does not directly support the systemic circulation. 
Therefore, there may be some value in combining retroper-
fusion with one of the other techniques to provide both 
myocardial and systemic support in some very high risk 
patients. 
Arterial blood perfusion (passive) or infusion (active) 
through the angioplasty catheter effectively prevents the 
onset of ischemia, allowing prolonged angioplasty balloon 
inflation times (7). The limitations of this technique are low 
flow rates, clot formation, inadequate driving pressure in 
severely hypotensive patients and a potential risk of perfo-
ration or dissection of the coronary artery with the catheter 
tip. Moreover, because it provides perfusion to the territory 
supplied by the vessel in which it is placed, global myocar-
dial perfusion is not provided as required in diffuse multi-
vessel disease. During abrupt vessel closure after removal of 
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the angioplasty balloon catheter and wire, recrossing the 
lesion may be unsuccessful in 30% to 50% of cases (39). 
Intracoronary perfusion of oxygenated Fluosol-DA 20% 
(Alpha Therapeutic Corporation), a fluosol emulsion, does 
improve left ventricular function, but does not return it to 
normal in experimental and clinical studies (8,9). There are 
also several limitations. It takes 30 to 40 min to defrost and 
oxygenate, which may limit its use in emergency situations; 
also, it is not as effective as arterial blood (40). Moreover, 
because of limitations in the total volume that may be 
infused, fluosol may be restricted in its use as support or 
maintenance therapy in failed angioplasty. 
Because all the myocardial support techniques require 
special catheters to be introduced through the target lesion 
of the coronary artery, when access is lost and cannot be 
regained rapidly, coronary venous retroperfusion may pro-
vide the only means of rapidly perfusing the myocardium 
until surgery. In addition, cardioprotective drugs and car-
dioplegia may be delivered effectively by this route in the 
presence of an arterial occlusion (27). 
Limitations of the study. In this study, a single precordial 
lead ECG was monitored. A 12 lead ECG or perhaps an 
epicardial electrogram would have provided a more sensitive 
marker of ischemia (41). Wall motion abnormality measure-
ment obtained by two-dimensional echocardiography was 
feasible in only 50% of patients. The supine position of the 
patient posed problems in attaining good echocardiographic 
windows. Cardiac hemodynamic variables such as cardiac 
index and stroke work index were not measured in this 
study. These variables were monitored in a study by Cos-
tantini et al. (26), who reported that retroperfusion signifi-
cantly improved cardiac index and stroke work index. Their 
results suggest that retroperfusion does preserve cardiac 
hemodynamics during ischemia. In this study, only short 
duration angioplasty balloon inflations were studied. The 
results in the complicated cases, however, indicate its po-
tential during prolonged ischemia. It is also important to note 
that this study deals with retroperfusion of the left anterior 
descending coronary artery territory only. The role of ret-
roperfusion in other vessel territories remains to be ade-
quately defined. 
Retroperfusion is invasive and requires two additional 
puncture sites. However, unlike intraaortic balloon pumping 
or cardiopulmonary bypass, the vascular complications have 
been negligible as a result of the smaller size sheaths. 
Significant vascular occlusive disease was not encountered 
in this study but may pose a problem. If retroperfusion is 
performed in conjunction with intraaortic balloon pumping 
or the cardiopulmonary pump system, a separate sheath and 
arterial catheter are not mandatory. Blood may be obtained 
from the side arm of the angioplasty sheath in extreme 
conditions. As mentioned earlier, to prevent jugular venous 
hematoma, left brachial insertion sites may be used. Lastly, 
it is important to note that this technique requires training in 
right heart and coronary sinus catheterization before it can 
be applied. 
Conclusions. This new synchronized coronary venous 
retroperfusion system was safe and feasible during coronary 
angioplasty. It significantly reduced and delayed the onset of 
ischemia during angioplasty and preserved regional and 
global myocardial function. It also reversed severe ischemia 
and cardiogenic shock during angioplasty complicated by 
abrupt coronary artery occlusion and supported these pa-
tients until definitive revascularization therapy was carried 
out. Retroperfusion thus appears to be an effective standby 
technique for high risk and complex coronary angioplasty 
and a support device in complicated and failed cases. 
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